news & views common adverse events were nausea, diarrhea and abdominal pain, which occurred to a similar extent in patients from both treatment groups.
lubiprostone is a bicyclic, fatty-acid metabolite analog of prostaglandin e1. this compound acts locally to activate ClC-2 chloride channels, and has been shown to activate apical ClC-2, but not cyclic-amP-dependent chloride channels (CFtr) in human cells. 2 lubiprostone is a member of a new class of compounds called prostones that are rapidly metab olized in the intestine and have very low systemic bioavailability. in contrast to prosta glandins, however, prostones do not stimulate smooth muscle contraction. as shown in Figure 1 , chloride concen tration in intestinal fluid is increased by activa tion of ClC-2, which results in increased secretion of chloride-rich enteric fluid and water transfer into the gut lumen without disturbing the serum electro lyte balance. the resultant fluid shift may stimulate motility and facilitate intestinal transit, which thereby improves the symptoms associated with altered bowel function in patients with chronic constipation and constipation-predominant iBs. 3 several features of the report by Drossman et al. deserve further comment. the response rates in both the treatment and placebo groups were quite low compared with those of other randomized, controlled trials in patients with iBs. However, as Drossman et al. used a unique (and apparently more conservative) definition of response, the authors suggested that their response rates may not be comparable to previously reported values. the clinical rele vance of using a conservative definition of response in functional gastrointestinal disorders is unclear, but use of such conserva tive definitions has accomplished the goal of reducing the reported placebo response in clinical trials in this area. Future studies that evaluate the clinical response of patients to lubiprostone treatment and use different definitions of response could shed light on the appropriateness of the end point used by Drossman et al.
the two trials in the report by Drossman et al. were statistically powered to exist as completely independent studies, which suggests that the decision to combine the trials for statistical analyses was made post hoc. the process of combining data from multiple independent studies into a single analysis is somewhat controversial. the aggregation of data from multiple trials should generally enhance the precision and accuracy of pooled results, but relies on the assumption that the differences between the studies primarily result from chance. the current report does not provide suffi cient information for the reader to assess the effects that might have resulted from subtle differences between the two studies. However, the analyses of combined data were stratified by study and individual results were also presented, which, in this instance, seems to provide suffi cient control and transparency.
Data that support a global improvement of symptoms are particularly important for the successful treatment of iBs. the mechanism by which lubiprostone might improve global symptoms such as abdominal pain in patients with iBs is, at this time, mostly speculative. visceral hyper sensitivity associ ated with iBs might result in part from altered intestinal permeability in the presence of a low-grade, chronic inflammatory response. 4 alternatively, chronic inflammation secondary to the presence of abnormal intestinal flora in the gut or bacterial overgrowth might lead to visceral hyper sensitivity. the restoration of tight junctions in the mucosa is hypothesized to have an effect on visceral afferent trans mission, but what would be the role of lubiprostone in this process? Findings from animal studies suggest that lubi prostone can restore tight junctions and improve mucosal function by activating ClC-2 channels. the resultant improved mucosal function might, therefore, result in a return to normal sensory function and reduced symptoms in patients with iBs and constipa tion. However, while studies such as those by Drossman et al. suggest that lubi prostone improves overall symptoms in patients with constipation-predominant iBs, the mechanisms by which it mediates multiple effects are poorly understood. Further study is, therefore, needed to provide direct evidence of the pathways by which lubi prostone acts to alleviate symptoms in patients with constipation-predominant iBs. Children and adolescents with untreated celiac disease display diseaserelated, histological alterations in the duodenal bulb, according to a new study. In 16 of the 665 patients enrolled in the study, lesions were confined to the duodenal bulb.
Celiac disease is a common chronic disorder with a prevalence that approaches 1% of the general population worldwide, although many cases remain unrecognized. 1 intestinal biopsy is currently the standard diagnostic test for celiac disease. 
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Collection and analy sis of multiple biopsy specimens obtained from the distal segments of the duodenum are recommended in anyone in whom celiac disease is suspected, irrespective of the results of serological tests or the endoscopic appearance of the duodenum.
2,3
Can biopsy specimens of the duodenal bulb be used for the diagnosis of celiac disease? studies in children and adolescent patients demonstrated that the characteristic lesions of celiac disease were present in the duodenal bulb in all patients with confirmed celiac disease, and the bulb was the only site where the celiac-disease-related, pathologic change was observed in some of these patients. 4, 5 Bonamico et al. 6 recently investigated this topic further in a multicenter study that had a larger sample size than other similar studies. 4, 5 During each endoscopy, one tissue sample was collected from the duodenal bulb, and three or four were collected from the distal duodenum. the bulb samples of all 665 children and adolescents with untreated celiac disease who were enrolled in the study displayed histological lesions of celiac disease, as evaluated in accordance with the marsh classification (as modified by oberhuber). more importantly, in 16 (2.4%) of the patients with celiac disease, the lesions were present only in the duodenal bulb. Conversely, none of the 348 age-matched and sex-matched controls showed any mucosal changes compatible with celiac disease in the duodenal bulb. the reason why the proximal intestine is more frequently affected by celiac disease than the distal intestine is unknown, but possible explanations are that the duodenum is the first part of the intestine to be reached by the antigenic peptides, or that a larger amount of partially digested gluten is present in the proximal intestine than in the distal intestine. 7, 8 usually, biopsy specimens used to diagnose celiac disease are taken from distal segments of the duodenum or from its second part.
3 endoscopic biopsy speci mens of the descending duodenum were initially shown to be as diagnostically revealing as jejunal specimens taken by capsule or suction tube. 9 Data from the early 1960s supports the propensity of the proximal intestine to injury in patients with untreated celiac disease. 8, 10 Furthermore, a wireless capsule endoscopy study published in 2008 demon strated that, in patients with untreated celiac disease, visually detectable damage to the proximal intestine (including the duo denum) is a very common finding, whereas jejunal injury in the absence of duodenal involvement is very rare. 7 the collection of duodenal biopsy specimens, therefore, seems to be an adequate strategy for diagnosis of celiac disease.
1,3 Currently, the collection of multiple biopsy specimens (between four and six) obtained from distal segments of the duodenum is recommended, because intestinal injury in celiac disease is patchy, the orientation of the biopsy specimens is variable (which increases the possibility of inconclusive histological diagnosis) and the presence of Brunner glands in the duo denal bulb could interfere in the evaluation of the villous:crypt ratio.
the study by Bonamico et al. confirms that, in children and adolescents with celiac disease, the mucosa of the duodenal bulb always shows celiac-disease-related pathological lesions. 6 this study also reports that the duodenal bulb was the only area of the intestine affected in 2.4% of children and adolescents with celiac disease, and that no mucosal changes compatible with celiac disease were observed in the duo denal bulb of controls. we propose the term 'short-segment celiac disease' to describe histological lesions that are restricted to the duodenal bulb.
this study has several limitations that need to be considered. no information on the number or expertise of pathologists who reviewed the biopsy specimens is provided; these data are very important, given the multicenter design of this study. How authors controlled potential interobserver and center-to-center variability, which may affect the results of the study, is not described either. an expert patho logical examination is essential for the correct identification of villous atrophy in the duodenal bulb, as the villi can be shorter than normal or even absent (pseudoflattening) in healthy mucosa that overlies Brunner glands. inexperienced pathologists are at risk of overestimation of atrophic lesions. 4 Data on the degree of mucosal injury in the duodenal bulb and distal duodenal segment observed in biopsy specimens were not provided. the question of whether the degree of villous atrophy in the distal segments of the duodenum is different from that of the duodenal bulb cannot, therefore, be answered. more than 80% of the patients with celiac disease showed total or subtotal villous atrophy, so an important investigation would be to evaluate the diagnostic accuracy of the duodenal bulb biopsy in patients who have milder intestinal damage than that present in Bonamico et al.'s population.
How c an cl i n i c i ans i nc or p or ate Bonamico et al.'s interesting findings 6 into practice? we believe that this study strongly supports a change to the commonly taught and practiced sampling of the distal segments of the duodenum alone in patients in whom celiac disease is suspected. Collection of biopsy specimens from the duodenal bulb in addition to those from distal segments of the duo denum should be recommended, as this practice may improve the rate of celiac disease detection in children and adolescents, particularly in those affected by short-segment celiac disease in whom the distal duodenum seems normal. serology provided important evidence that supports the presence of celiac disease in patients with pathology limited to the duodenal bulb. 6 whether Bonamico et al.'s findings apply to adults, who have a higher prevalence of peptic ulcer disease and nsaiD use than children or adolescents, however, remains to be proven. Finally, as the frequency of complica tions related to diagnostic endo scopy with biopsy of the distal duodenum is very low, prospective studies need to investigate whether the rate of complications (that is, perforation) would be adversely affected by the routine collection of biopsy samples from the duodenal bulb. 
